Objective — to explore the prevalence of urogenital infections, to assess their risk factors in women with chronic recurrent cystitis, to study the etiological value of Chlamydia trachomatis in its development, and to define the clinical and bacteriological efficacy of nifuratel in the combination treatment of patients with chronic recurrent cystitis associated with Ch. trachomatis. Subject and methods. In the period 2000 to 2017, clinical and laboratory examinations were made in 836 women aged 20 to 40 years with chronic recurrent cystitis; of them 421 (50.1%) patients were found to have chronic urogenital infection. Preoperative clinical and etiological examinations (urine microscopic and bacteriological examination, material collection from the urethra, vagina and cervical canal for urogenital infections) were carried out in all the patients. A culture method (inoculation into the McCoy medium), direct immunofluorescence, and polymerase chain reaction were used to detect Ch. trachomatis in the clinical specimens obtained by scraping from the urethra, vagina, and cervical canal. Enzyme immunoassay was applied to investigate the production of immunoglobulins. Results. Ch. trachomatis was found to be of etiological significance in the development of chronic cystitis; nifuratel was determined to be clinically and bacteriologically effective in the combination of therapy for patients with chronic recurrent cystitis associated with Ch. trachomatis. Conclusion. The highest values of clinical and bacteriological effectiveness were achieved 2 months after the end of treatment with a combination of josamycin and nifuratel. These etiotropic therapy regimens may be recommended for wide use in the treatment of chronic recurrent cystitis in women.